An official website of the United States government
AD-Related Dementias Focus
Enrich the design of trials of vascular health interventions to improve their application to AD/ADRD among aging diverse populations.
2028 RFA-NS-20-012: Clinical Trials Planning for Symptomatic Vascular Contributions to Cognitive Impairment and Dementia (VCID) NOT-NS-21-047: Administrative Supplements to Promote Diversity for NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Awardees 10.G In Progress DN ADRD Summit 2016: Health Disparities (HD), Focus Area 1: Treatment and Prevention Strategies, Milestone 2 (PDF, 901K) Workshop: Health Disparities and Inequities in Neurological Disorders Trial Design Select projects funded in FY21 Select projects funded in FY22 Diverse Vascular Contributions to Cognitive Impairment and Dementia (VCID) The DISCOVERY (Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY) Network
- Develop, implement, and validate guidelines for brain health assessments in clinical trials of vascular interventions in aging, diverse populations.
Summary of Key Accomplishments
NIH supports research tools and biomarkers to detect vascular cognitive impairment (VCID) in diverse populations that can be used in clinical trials. Diverse-VCID is an NINDS funded 6-year national study of 2,250 Americans from diverse backgrounds to understand the role that cerebrovascular disease plays in developing Alzheimer’s disease and other dementias. Multiple clinical sites throughout the country with expertise in recruitment and retention of ethnic/racial minority adult participants have been selected. Diverse-VCID uses advanced brain imaging and blood-based techniques to understand how vascular changes in late life cause brain injuries that lead to cognitive decline. This project leverages resources from the NIH-funded MarkVCID initiative, which has developed and validated several VCID biomarker kits, which are designed to measure vascular changes that predict development of cognitive impairment and dementia and serve as biomarkers to test preventative therapies.
The key accomplishments summary is current as of July 2022.